Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

181025 ppsc company presentation by saman honarnejad (smb living lab meeting 25 10-18)

6 views

Published on

Presentation by Saman Honarnejad SMB-Meeting dd 25-10-2018

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

181025 ppsc company presentation by saman honarnejad (smb living lab meeting 25 10-18)

  1. 1. Pivot Park Screening Centre Your Partner in Screening & Automation Dr. Saman Honarnejad Team Leader Assay Development
  2. 2. Pivot Park Screening Centre (PPSC) What • PPSC is an independent Contract Research Organization (CRO) specialized in early drug discovery services Services • Biochemical and cell-based assay development • Medium to (ultra) high-throughput screening (uHTS) • H2L biological profiling 3 PPSC 25 Oct 2018
  3. 3. Medication for a healthier society • The pharma world is changing: adoption of open innovation and externalization of activities • Starting points for new medicines are identified at PPSC • Pivot Park Screening Centre is the centre of expertise for early drug discovery PPSC 25 Oct 2018 4
  4. 4. Mission and Vision Mission With our partners we accelerate the discovery of new medicines for a healthier society. Vision Our long-standing experience in early drug discovery and our state-of-the-art (ultra) High Throughput Screening infrastructure provides our partners with the best confirmed leads. We are valued as a flexible, efficient, transparent and innovative company. PPSC 25 Oct 2018 5
  5. 5. Screening history in Oss (The Netherlands) 1995 2000 2005 2010 2015 Introduction MTS & HTS Biochemical and cellular screening ASPIRE: Integrated in-vitro screening platform uHTS: capacity & miniaturisation Closure of research @ Oss New legal Entity 2012 1st HTS in January 2013 6 PPSC 25 Oct 2018
  6. 6. Dutch Life Sciences in Oss PPSC 25 Oct 2018 7
  7. 7. A unique science park for drug discovery in Oss, NL Pivot Park CMO’s Other Services Product Development CRO’s PPSC 25 Oct 2018 8
  8. 8. High Throughput Screening is our core business PPSC in the drug discovery process $20 billion Target Discovery Hit finding Hit to lead Lead series Phase I, II Phase III & registration Sales € Compound Value Years 3 5 7 11 13 $50M $500M $2 billion Pre-clinical development $100M >159 PPSC 25 Oct 2018 9
  9. 9. High Throughput Screening is our core business PPSC in the drug discovery process $20 billion Target Discovery Hit finding Hit to lead Lead series Phase I, II Phase III & registration Sales € Compound Value Years 3 5 7 11 13 $50M $500M $2 billion Pre-clinical development $100M >159 PPSC 25 Oct 2018 9
  10. 10. General capabilities • Assay development • Cell culturing • Sample handling • Screening • Biochemical and cellular assays • single point/dose responses • Automation of in-vitro experiments • lots of different dispensing equipment • Optimization of automation protocols • 96, 384, 1536 well • Automated data processing • Assay panels • Kinase/GPCRs/proteases/redox/CYPs • High content analysis • Tox testing • Cytokine analysis • Cardiomyocytes and neuronal cells PPSC 25 Oct 2018 10
  11. 11. HTS workflow & terminology 300,000+ 100 5 Compound Collection Leads Confirmed actives Actives Confirmed hits Assay development Triaging uHTS Hit to lead PPSC 25 Oct 2018 11
  12. 12. PPSC is active in many therapeutic areas Broad target class portfolio 20% 5% 9% 4% 2% 23% 13% 3% 7% 14% Protease Lipase Kinase Transferase Ligase Other enzyme PPI Ion channel Receptor Other PPSC 25 Oct 2018 12
  13. 13. 300,000 drug-like compounds for HTS • Diversity based libraries • Purity > 95% at time of purchase • Circa 50% available at PPSC as solid compound for quick follow-up • Freedom to progress hits from libraries 130K historical collection 87K acquired 2012 8K pharma origin 70K BioAscent extention PPSC 25 Oct 2018 13
  14. 14. Flexible access to (shared) libraries Expansion through collaborations Unique library, Includes 200K “public library” Unique PPSC capability PPSC 300K compounds ELF ESCulab 550K compounds Pharma Clients 300K to >1M compounds PPSC 25 Oct 2018 14
  15. 15. Fully automated dataprocessing INPUT SOURCES ASSAY PLATE PREPARATION ASSAY DECISION MAKING CALCULATION VALIDATION Automated Sample Tracking (SAMTRACK) ActivityBase XE Data Mining Plates Tests Results Source-multiple intermediates-assay plate Raw data Experiment definition Screening quality control Data authori- zation Triage PPSC 25 Oct 2018 15
  16. 16. Demonstrated as number of data points Increasing HTS production 0 2,000,000 4,000,000 6,000,000 8,000,000 10,000,000 12,000,000 14,000,000 2013 2014 2015 2016 2017 Commercial Shared Risk ELF 16 Year Numberofdatapoints PPSC 25 Oct 2018
  17. 17. Unique Selling Points uHTS large libraries Pharma experts ELF screening site
  18. 18. Screening history Oss (The Netherlands) 1995 2000 2005 2010 2015 Introduction MTS & HTS Biochemical and cellular screening ASPIRE: Integrated in-vitro screening platform uHTS: capacity & miniaturisation Closure of research @ Oss New legal Entity 2012 1st HTS in January 2013 HTS 100 March 2018 PPSC 25 Oct 2018 18
  19. 19. Product portfolio Assay development AD-labs uHTS uHTS-robot H2L support ASPIRE-system(s) ~1-9 months ~2-3 months Biweekly - ~12 months Automation support ASPIRE-system(s)Days/weeks Activity Project duration Facilities Compound library uHTS/ASPIRE PPSC 25 Oct 2018 19
  20. 20. Automation of in-vitro experiments The HTS and open access lab • Efficient, flexible and versatile • Worry-free open access • Broad range of life science applications Automated workflows High Content Analysis (Imaging) Multimode readers FLIPR Tetra Pipetting robots PPSC 25 Oct 2018 20
  21. 21. High Content Analysis • Micronucleus Assay • Nuclear Fragmentation assay • Cell proliferation • Phospholipidosis assay • Cytotoxicity 0 0.05 0.1 0.15 0.2 0.25 Fragmentationindex Nuclear Fragmentation HELA cells 3e-5M Staurosporine DMSO control Z’= 0.79 S/B= 2.2 0 20 40 60 80 100 120 1.00E-091.00E-081.00E-071.00E-061.00E-051.00E-041.00E-03 %effect [Staurosporine] M Nuclear Fragmentation HELA cells PPSC 25 Oct 2018 21
  22. 22. Open access lab • Open Innovation • Access for academia and SME’s • Shared facilities at Pivot Park • Automation and scale-up of client’s production • Promotion for Pivot Park PPSC 25 Oct 2018 22
  23. 23. Grants and shared risk projects PPSC as partner in collaborations • European Lead Factory ‒ 30 partners, 7 from EFPIA ‒ 72 HTS programs completed in 5 year • Cancer Drug Discovery Initiative (CDDI) ‒ Netherlands Cancer Institute and Leiden University ‒ Joint program to develop clinical candidates in oncology • Center Of Innovative LEad Discovery (COILED) ‒ Radboud Univ Med Center, Radboud University (Chemistry), Pansynth, BioAxis, Inntrest ‒ Joint program to develop clinical candidates in epigenetics PPSC 25 Oct 2018 23
  24. 24. Drug discovery consortia CDDI TKI COILED PPSC 25 Oct 2018 24
  25. 25. European Lead Factory Public contribution (200,000 cpds by May 2018) PHARMA contribution (>300,000 cpds) - Compound logistics - uHTS - Hit triage - Medicinal Chemistry Joint European Compound Library European Screening Centre LIBRARY DESIGNS DRUG TARGETS The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115489, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. PPSC 25 Oct 2018 25
  26. 26. ELF Partners Chemistry CROs EFPIA partners Public Compound Consortium funded by European Screening Centre PPSC 25 Oct 2018 26
  27. 27. PPSC performs all public screening ELF operates at industry scale Assay ready for u-HTS Hit follow-up work finished Improved Hit List delivered Submitted Target Proposals Accepted Target Programmes Ultra-HTS performed Qualified Hit List delivered 88 78 72 72 72 35162 52 Completed 6 Withdrawn 45% Rejected PPSC 25 Oct 2018 27
  28. 28. Thank you! For more information please contact: Pivot Park Screening Centre Oss, The Netherlands +31-412-846050 www.ppscreeningcentre.com Helma Rutjes, PhD, COO Helma.rutjes@ppscreeningcentre.com Ronald ten Berge, PhD, CBO ronald.tenberge@ppscreeningcentre.com Saman Honarnejad, PhD, Team Leader Saman.honarnejad@ppscreeningcentre.com

×